FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Cefixime for Oral Suspension 200 mg/5 mL Recall

Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspens…

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Jun 26, 2024
Recall ID
D-0559-2024
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Cefixime for Oral Suspension 200 mg/5 mL starting May 30, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0559-2024 on Jun 26, 2024. Reason: Failed Content Uniformity Specifications. Status: Terminated.

Why it was recalled

Failed Content Uniformity Specifications

Product description

Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03

Lot numbers, UPCs & expiration codes

Lot F201519, Expiry: November 2024

Where it was sold

Nationwide in the US

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0559-2024
Classification
Class II
Status
Terminated
Recall initiated
May 30, 2024
FDA report date
Jun 26, 2024
Quantity
3,552 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0559-2024, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
94723
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
Lot F201519, Expiry: November 2024
Postal code
21202-6174
Report date
Jun 26, 2024
Product type
Drugs
Recall number
D-0559-2024
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
3,552 bottles
Termination date
Apr 29, 2025
Reason for recall
Failed Content Uniformity Specifications
Voluntary / mandated
Voluntary: Firm initiated
Product description
Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03
Distribution pattern
Nationwide in the US
Recall initiation date
May 30, 2024
Initial firm notification
Letter
Center classification date
Jun 18, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0559-2024, published Jun 26, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls